Celine Bio

Immune-mediated therapies like cell therapy and protein therapeutics holds the key to cure a wide range of diseases. However, more than 70% of the clinical trials failed due to lack of specificity that leads to higher toxicity and poor efficacy for the patients. Celine’s proprietary technology platform is designed to overcome the current clinical limitations, develop de novo patient-tailored therapeutics, and accelerate access to life-saving treatments. Celine’s technology platform integrates synthetic biology, high-throughput screening, and de novo protein designs with the power of generative AI to precisely program and deliver targeted immune-mediated therapies to the right place in the body and expand targetable landscape to save millions of patients’ lives. Our technology has been validated in vitro and in vivo across different cancer tumors and modalities (Bi-Specific T Cell Engager and Cell Therapy (CAR-T/CAR-NK)).

Immune-mediated therapies like cell therapy and protein therapeutics holds the key to cure a wide range of diseases like Cancer, Immune diseases, and many more with massive global patient need. However, more than 70% of the clinical trials failed due to lack of specificity that leads to higher toxicity and poor efficacy for the patients. Conventional therapeutics have limited ability to reach specific cells in the body; it is like the world before GPS. The current trial-n-error approach makes it so costly for patients ($750K-$1M).

Celine has conquered this problem by integrating proprietary control modality, synthetic biology, and de novo protein designs with the power of generative AI to precisely design and deliver targeted immune-mediated therapies to the right place in the body at the right time. We are pioneering a unique approach to activate right therapy at the right place, expand targetable landscape, and automate the patient-tailored discovery process to improve safety and efficacy. This allows us to exert finely tuned control of cell behaviors and remotely control cell functions with real-time monitoring. Through high-throughput screening and precise genetic reprogramming, we equip therapeutic cells with novel immune sensors, fine-tuned cell signaling control, and develop de novo patient-tailored therapeutics. Our technology has been validated in vitro and in vivo across different cancer tumors and modalities (Bi-Specific T Cell Engager and Cell Therapy (CAR-T/CAR-NK)).